In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions

ABSTRACT Early stage developability assessments of monoclonal antibody (mAb) candidates can help reduce risks and costs associated with their product development. Forecasting viscosity of highly concentrated mAb solutions is an important aspect of such developability assessments. Reliable predictions of concentration-dependent viscosity behaviors for mAb solutions in platform formulations can help screen or optimize drug candidates for flexible manufacturing and drug delivery options. Here, we present a computational method to predict concentration-dependent viscosity curves for mAbs solely from their sequence—structural attributes. This method was developed using experimental data on 16 different mAbs whose concentration-dependent viscosity curves were experimentally obtained under standardized conditions. Each concentration-dependent viscosity curve was fitted with a straight line, via logarithmic manipulations, and the values for intercept and slope were obtained. Intercept, which relates to antibody diffusivity, was found to be nearly constant. In contrast, slope, the rate of increase in solution viscosity with solute concentration, varied significantly across different mAbs, demonstrating the importance of intermolecular interactions toward viscosity. Next, several molecular descriptors for electrostatic and hydrophobic properties of the 16 mAbs derived using their full-length homology models were examined for potential correlations with the slope. An equation consisting of hydrophobic surface area of full-length antibody and charges on VH, VL, and hinge regions was found to be capable of predicting the concentration-dependent viscosity curves of the antibody solutions. Availability of this computational tool may facilitate material-free high-throughput screening of antibody candidates during early stages of drug discovery and development.

[1]  Takahiro Suzuki,et al.  Prediction of liquid viscosity for organic compounds by a quantitative structure–property relationship , 2000 .

[2]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[3]  T. Creighton.  The Physical and Chemical Basis of Molecular Biology , 2010 .

[4]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[5]  Janice M. Reichert,et al.  Which are the antibodies to watch in 2013? , 2013, mAbs.

[6]  Bernhardt L Trout,et al.  Computational tool for the early screening of monoclonal antibodies for their viscosities , 2016, mAbs.

[7]  Li Li,et al.  Concentration Dependent Viscosity of Monoclonal Antibody Solutions: Explaining Experimental Behavior in Terms of Molecular Properties , 2014, Pharmaceutical Research.

[8]  Sandeep Yadav,et al.  Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. , 2012, Biophysical journal.

[9]  Ken A. Dill,et al.  In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability , 2014, Proceedings of the National Academy of Sciences.

[10]  Paul Labute,et al.  Calibrative approaches to protein solubility modeling of a mutant series using physicochemical descriptors , 2010, J. Comput. Aided Mol. Des..

[11]  Malik Beshir Malik,et al.  Applied Linear Regression , 2005, Technometrics.

[12]  Jennifer Sims,et al.  Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies , 2010, mAbs.

[13]  K. Whaley,et al.  Antibody diffusion in human cervical mucus. , 1994, Biophysical journal.

[14]  H. Sathish,et al.  Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering , 2016, mAbs.

[15]  S. I. Kreps,et al.  Prediction of Viscosity of Liquid Hydrocarbons , 1970 .

[16]  Li Li,et al.  Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development , 2016, mAbs.

[17]  J. Reichert.  Antibodies to watch in 2016 , 2016, mAbs.

[18]  Sandeep Kumar,et al.  Disulfide Scrambling in IgG2 Monoclonal Antibodies: Insights from Molecular Dynamics Simulations , 2011, Pharmaceutical Research.

[19]  L. J. Harris,et al.  Refined structure of an intact IgG2a monoclonal antibody. , 1997, Biochemistry.

[20]  Ning Ma,et al.  IgBLAST: an immunoglobulin variable domain sequence analysis tool , 2013, Nucleic Acids Res..

[21]  Hongcheng Liu,et al.  Disulfide bond structures of IgG molecules , 2012, mAbs.

[22]  S. Harding,et al.  The concentration-dependence of macromolecular parameters. , 1985, The Biochemical journal.

[23]  Daniel Cabrol-Bass,et al.  Estimation of the Liquid Viscosity of Organic Compounds with a Quantitative Structure-Property Model , 1999, J. Chem. Inf. Comput. Sci..

[24]  C. E. Rogers,et al.  Symbolic Description of Factorial Models for Analysis of Variance , 1973 .

[25]  Ali S. Hadi,et al.  Variable Selection Procedures , 2006 .

[26]  L. Harrison,et al.  Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model , 2014, Clinical & translational immunology.

[27]  Christopher J Roberts,et al.  Protein aggregation and its impact on product quality. , 2014, Current opinion in biotechnology.

[28]  S. D. Hudson,et al.  Critical examination of the colloidal particle model of globular proteins. , 2015, Biophysical journal.

[29]  S. Weisberg.  Applied Linear Regression: Weisberg/Applied Linear Regression 3e , 2005 .

[30]  L. Serrano,et al.  Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins , 2004, Nature Biotechnology.

[31]  G. Scapin,et al.  Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab , 2015, Nature Structural &Molecular Biology.

[32]  P. M. Buck,et al.  Impact of deglycosylation and thermal stress on conformational stability of a full length murine igG2a monoclonal antibody: Observations from molecular dynamics simulations , 2013, Proteins.

[33]  Li Li,et al.  Rational design of viscosity reducing mutants of a monoclonal antibody: Hydrophobic versus electrostatic inter-molecular interactions , 2015, mAbs.

[34]  E. Padlan,et al.  Anatomy of the antibody molecule. , 1994, Molecular immunology.

[35]  Sandeep Kumar,et al.  Assessment of Physical Stability of an Antibody Drug Conjugate by Higher Order Structure Analysis: Impact of Thiol- Maleimide Chemistry , 2014, Pharmaceutical Research.

[36]  Anuj Chaudhri,et al.  Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. , 2015, Molecular pharmaceutics.

[37]  R. Nussinov,et al.  Temperature range of thermodynamic stability for the native state of reversible two-state proteins. , 2003, Biochemistry.